Good morning :)
$
₹
TransMedics Group Inc

TransMedics Group Inc

TMDX

NASDAQ
Asset Logo

TransMedics Group Inc

TMDX

NASDAQ
$82.153.39% (-2.88)
$
₹
$82.153.39% (-2.88)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Medical Devices

Mid Cap

With a market cap of $3.0B the stock is ranked 1884

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

22.38
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

5.90
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$3.86
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.75
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

22.68%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 9 analysts' reports

Buy
6 analysts
Hold
3 analysts
Sell
0 analyst

Analysts expect a +18.40% price upside over the next year

Current Price$82.15
Target Price$97.3

Company Profile

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Peers

Peers

Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
34.16
34.16
1Y Return
21.73%
21.73%
Buy Reco %
74.07
74.07
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
36.64
36.64
1Y Return
2.73%
2.73%
Buy Reco %
88.00
88.00
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
40.50
40.50
1Y Return
19.01%
19.01%
Buy Reco %
66.66
66.66
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
22.63
22.63
1Y Return
2.75%
2.75%
Buy Reco %
53.12
53.12
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
28.65
28.65
1Y Return
28.96%
28.96%
Buy Reco %
68.75
68.75

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
TransMedics Group Inc 22.385.900.75
Abbott Laboratories34.163.571.93
Danaher Corporation36.642.741.22

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

143.8
24.3
160.7
105.3
173.9
7.3
189.9
14.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue96.85114.30108.76121.62143.53157.37143.82160.76173.93189.94
Net Income12.1912.194.216.8525.6834.9024.31105.387.3114.68
Net Profit Margin12.59%10.66%3.87%5.63%17.89%22.18%16.90%65.55%4.20%7.72%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. TransMedics Group Inc (TMDX) share price today is $82.15 as of September 12, 2026 at 1:30 AM IST. The stock touched a day high of $85.70 and a day low of $79.29.

  2. TransMedics Group Inc stock trades on NASDAQ under the ticker symbol TMDX.

  3. TransMedics Group Inc's market capitalization is $2.99B as of September 12, 2026 at 1:30 AM IST.

  4. TransMedics Group Inc's price-to-earnings (P/E) ratio is 22.38 as of September 11, 2026.

  5. TransMedics Group Inc's price-to-book (P/B) ratio is 5.90 as of September 11, 2026.

  6. Yes, You can buy TransMedics Group Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy TransMedics Group Inc shares in three steps: 1. Search TransMedics Group Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since TransMedics Group Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in TransMedics Group Inc (TMDX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.1217 shares at the current price of $82.15.

Loading...